You have 9 free searches left this month | for more free features.

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Eli Lilly and Company (2)

Collaborator

AurKa Pharma Inc. (1)

Loxo Oncology, Inc. (1)

Merck Sharp & Dohme LLC (1)

Intervention

ly3295668 (2)

abemaciclib (1)

cetuximab (1)

erlotinib (1)

ly3537982 (1)

pembrolizumab (1)

temuterkib (1)

tno155 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

ly3295668

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Tumors, Tumor Metastasis, Triple Negative Breast Tumors Trial in Edmonton, Montreal (LY3295668)

Completed

Neoplasms
+6 more

LY3295668

Edmonton, Alberta, Canada
+2 more

Jun 29, 2021

NSCLC, Colorectal Neoplams, Endometrial Tumors Trial in Worldwide (LY3537982, Abemaciclib, Erlotinib)

Recruiting

Carcinoma, Non-Small-Cell Lung
+4 more

LY3537982
+7 more

Los Angeles, California
+21 more

Jul 22, 2022